Bausch Health and the pan-Canadian Pharmaceutical Alliance sign for CABTREO

Bausch Health, Canada Inc. has entered into a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for public coverage of CABTREO, an acne treatment gel, for patients 12 years of age and older. This decision marks a step toward inclusion of the treatment in Canadian public plans.

Approved by Health Canada, CABTREO is the first topical solution with a triple therapeutic action, combining an antibiotic, retinoid, and antibacterial agent. Phase 3 clinical trials have demonstrated a significant reduction in acne lesions, with a notable improvement in 50% of patients after 12 weeks.

The product is contraindicated for people with hypersensitivity to its components or with certain medical conditions. Its efficacy and approval reflect Bausch Health's commitment to expanding its innovative dermatology portfolio.